Shopping Cart
- Remove All
- Your shopping cart is currently empty
Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 1.881 € | In Stock | |
5 mg | 3.952 € | In Stock | |
10 mg | 5.339 € | In Stock | |
25 mg | 7.942 € | In Stock | |
50 mg | 10.640 € | In Stock | |
100 mg | 14.440 € | In Stock |
Description | Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A. |
In vivo | Emicizumab (1.5-10 mg/kg; i.v.; 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia type A bleeding model with an FVIII equivalent of 9 U/dL.[1]
Emicizumab (3 mg/kg; intravenously) provides additional hemostatic activity when combined with low-dose FVIII (10 U/dL).[1] |
Alias | RO 5534262, ACE 910 |
Molecular Weight | 145.14 kDa |
Cas No. | 1610943-06-0 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.